Header

UZH-Logo

Maintenance Infos

Stereotactic body radiotherapy in operable patients with stage I NSCLC: where is the evidence?


Guckenberger, Matthias (2015). Stereotactic body radiotherapy in operable patients with stage I NSCLC: where is the evidence? Expert Review of Anticancer Therapy, 15(5):525-530.

Abstract

This review summarizes the evidence of stereotactic body radiotherapy (SBRT) as an alternative to surgery (lobectomy and sublobar resection) for stage I NSCLC. Three randomized trials comparing SBRT and surgery were initiated but all three were stopped early due to poor accrual. As the next level of evidence, results from matched-pair analyses performed in single-institutional (n = 4), multi-institutional (n = 3) and population-based (n = 3) settings are available. There was close agreement between all studies that SBRT is at least equivalent to sublobar resection making it the preferred treatment for a high-risk population. SBRT was equivalent to lobectomy in the endpoints of loco-regional control and cancer-specific survival. Disease-free survival and overall survival were inferior after SBRT compared with lobectomy in one and two studies, respectively, and not significantly different in all other studies. Consequently, for patients without relevant comorbidities, who are accepting the risk of a surgical procedure, lobectomy remains the standard of care.

Abstract

This review summarizes the evidence of stereotactic body radiotherapy (SBRT) as an alternative to surgery (lobectomy and sublobar resection) for stage I NSCLC. Three randomized trials comparing SBRT and surgery were initiated but all three were stopped early due to poor accrual. As the next level of evidence, results from matched-pair analyses performed in single-institutional (n = 4), multi-institutional (n = 3) and population-based (n = 3) settings are available. There was close agreement between all studies that SBRT is at least equivalent to sublobar resection making it the preferred treatment for a high-risk population. SBRT was equivalent to lobectomy in the endpoints of loco-regional control and cancer-specific survival. Disease-free survival and overall survival were inferior after SBRT compared with lobectomy in one and two studies, respectively, and not significantly different in all other studies. Consequently, for patients without relevant comorbidities, who are accepting the risk of a surgical procedure, lobectomy remains the standard of care.

Statistics

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Radiation Oncology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:May 2015
Deposited On:24 Nov 2015 14:14
Last Modified:08 Dec 2017 14:10
Publisher:Expert Reviews
ISSN:1473-7140
Publisher DOI:https://doi.org/10.1586/14737140.2015.1023190
PubMed ID:25761997

Download

Full text not available from this repository.
View at publisher